| Field | Specification |
|---|---|
| Alternative names | HPBRSM |
| Species | |
| Applications | |
| Cell type | |
| Classification | |
| Tissue | |
| Disease | Hypertension |
| Growth properties | |
| Biosafety level | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Overview
Human Hypertension Brochial Smooth Muscle Cells are primary cells derived from human hypertension brochial tissue hypertension context. Product metadata indicate an in vitro culture model with smooth muscle-like morphology and a reported BSL-2 handling context. Depending on the selected variant, the product may be supplied in selectable cryopreserved and flask formats (Frozen Vial (0.5 x 10^6 cells), T25 Flask, and T75 Flask) for in vitro studies that benefit from tissue-relevant cellular context.
Key elements and design rationale
- Source and identity reflect the stated cells model and tissue origin, supporting experiments where hypertension brochial/musculoskeletal context matters.
- Reported classifications and phenotype descriptors include primary, smooth muscle-like morphology, and disease context: Hypertension.
- Selectable variants can include Frozen Vial (0.5 x 10^6 cells), T25 Flask, and T75 Flask; choose the listed format according to culture scale, handling preference, and downstream assay design.
- Handling considerations should follow institutional practice appropriate for the reported BSL-2 classification and the datasheet associated with the selected format.
Review the specification table and variant selector together when choosing the appropriate format for assay scale, tissue context, and downstream readouts.
Biological background
This cell model supports in vitro studies where tissue context, donor source, growth state, and phenotype-associated readouts are important for experimental interpretation. In this case, the stated hypertension brochial tissue and musculoskeletal context can influence morphology, baseline signaling, and assay responsiveness. The listed disease context (Hypertension) may also be relevant when comparing baseline phenotype or response profiles.
Research relevance and current trends
- Tissue-specific cell-state differences remain important when selecting in vitro models for mechanistic and comparative studies.
- Multiparametric readouts such as cell culture, protein analysis, and imaging are commonly combined to connect morphology, phenotype, and pathway-level response.
- Comparisons across donor source, passage, tissue origin, or model state can help separate model-specific effects from assay-specific effects.
Common research applications
- Cell culture and condition-optimization studies to assess morphology, growth behavior, or baseline phenotype over time.
- Protein-level analyses to monitor phenotype-associated markers, pathway activation, or secreted factors.
- Imaging-based workflows to track morphology, localization, marker expression, cell-cell interactions, or reporter-linked signal.
- Flow-cytometry workflows to profile marker expression, viability, reporter-positive fractions, or phenotypic shifts.
Changes in morphology, marker expression, proliferation, migration, barrier properties, reporter activity, or secreted factors are typically interpreted alongside matched controls and the selected culture conditions.
Notes for experimental interpretation
- Potential confounders include donor-to-donor variability, passage-dependent phenotypic drift, substrate effects, serum or media composition, and differences between cryopreserved and expansion-stage material.
- Use matched controls and confirm identity with morphology- and marker-based readouts suited to the stated cell type, tissue source, and downstream assay.
Customization & Add-ons: Can't find the cell line you need—or require a custom cell-based solution for your project? We can help you source the best match or support custom cell line services for diverse research needs, including cell line sourcing and selection (species, tissue, and disease model matching), stable cell line engineering (overexpression, knockdown, or knockout via CRISPR/Cas9, shRNA, or sgRNA), reporter gene integration (GFP, RFP, luciferase, and other fluorescent or bioluminescent constructs), genome editing and knockin (point mutations, tagged endogenous proteins, conditional alleles), inducible expression systems (Tet-On/Off and other regulatable constructs), drug resistance marker selection (puromycin, G418, hygromycin, and others), custom growth and media optimisation for specific assay requirements, scale-up production for high-throughput screening campaigns, and authentication and QC services (STR profiling, mycoplasma testing, viability assessment). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
